Clinical trial of indomethacin in Alzheimer's disease.
In a 6-month, double-blind, placebo-controlled study, 100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer's disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tests, indomethacin patients improved 1.3% (+/- 1.8%), whereas placebo patients declined 8.4% (+/- 2.3%)--a significant difference (p < 0.003). Caveats include adverse reactions to indomethacin and the limited scale of the trial.
Rogers
J
J
L.J. Roberts Center for Alzheimer's Research, Sun Health Research Institute, AZ 85372.
Kirby
L C
LC
Hempelman
S R
SR
Berry
D L
DL
McGeer
P L
PL
Kaszniak
A W
AW
Zalinski
J
J
Cofield
M
M
Mansukhani
L
L
Willson
P
P
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D008297:Male; D009483:Neuropsychological Tests; D010919:Placebos
D010919:Placebos; D007213:Indomethacin